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Background/Aims: Although the use of surveillance 18F-fluorodeoxyglucose (FDG) 
positron emission tomography/computed tomography (PET/CT) is discouraged in 
patients with diffuse large B-cell lymphoma, its usefulness in different subtypes 
has not been thoroughly investigated.
Methods: We retrospectively evaluated 157 patients who showed positive results on 
surveillance FDG-PET/CT every 6 months following complete response for up to 
5 years. All of the patients also underwent biopsies.
Results: Seventy-eight (49.6%) of 157 patients had true positive results; the remain-
ing 79 (50.3%), including eight (5.1%) with secondary malignancies, were confirmed 
to yield false positive results. Among the 78 patients with true positive results, the 
disease in seven (8.9%) had transformed to a different subtype. The positive pre-
dictive value (PPV) of FDG-PET/CT for aggressive B-cell non-Hodgkin’s lympho-
ma (NHL) was lower than that for indolent B-cell or aggressive T-cell NHL (p = 0.003 
and p = 0.018, respectively), especially in patients with a low/low-intermediate 
international prognostic index (IPI) upon a positive PET/CT finding. On the other 
hand, indolent B-cell and aggressive T-cell NHL patients showed PPVs of > 60%, 
including those with low/low-intermediate secondary IPIs.
Conclusions: The role of FDG-PET/CT surveillance is limited, and differs ac-
cording to the lymphoma subtype. FDG-PET/CT may be useful in detecting early 
relapse in patients with aggressive T-cell NHL, including those with low/low-in-
termediate risk secondary IPI; as already known, FDG-PET/CT has no role in ag-
gressive B-cell NHL. Repeat biopsy should be performed to discriminate relapse 
or transformation from false positive findings in patients with positive surveil-
lance FDG-PET/CT results.
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INTRODUCTION
Positron emission tomography (PET) alone or com-
bined with computed tomography (PET/CT) using flu-
orine 18F-fluorodeoxyglucose (FDG) is a highly sensitive 
and non-invasive imaging modality that is widely used 
for patients with malignant lymphoma. It is an essen-
tial imaging tool for evaluating the extent of disease at 
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diagnosis, response assessment, and restaging of pa-
tients with FDG-avid lymphoma [1,2]. The International 
Working Group revised the response criteria for incor-
porating FDG-PET/CT in diffuse large B-cell lymphoma 
(DLBCL) and Hodgkin’s lymphoma (HL) [2]. Although 
data acquired from interim FDG-PET/CT imaging are 
insufficient to modify treatment strategies, the utility 
of risk-adapted therapies based on such interim FDG-
PET/CT findings has been widely investigated [3,4]. On 
the other hand, the current recommendations discour-
age the use of FDG-PET/CT for surveillance [5]. Many 
studies on surveillance imaging found that using FDG-
PET-CT for routine follow-up did not reliably detect 
early relapse, especially in patients with curable lym-
phomas [6-8]. Routine radiologic imaging is associated 
with a number of drawbacks, including excessive cost, 
lead-time bias, cancer risk related to radiation exposure, 
and patient anxiety [9,10]. Moreover, FDG-PET/CT also 
produces a high false positive rate, which can lead to un-
necessary biopsies [5,11].
 Nevertheless, some studies suggested that surveil-
lance FDG-PET/CT could be useful for a highly selected 
population of lymphoma. For example, elderly patients 
over 60 years or DLBCL patients with a baseline inter-
national prognostic index (IPI) ≥3 in the first 18 months 
have been shown to benefit from surveillance FDG-
PET/CT [12,13]. Furthermore, different lymphoma sub-
types carry varying prognoses in clinical practice, and 
relapsed lymphomas show different clinical courses ac-
cording to disease aggressiveness. Aggressive non-Hod-
gkin’s lymphoma (NHL) has a short relapse window, 
while indolent NHL has a long asymptomatic period be-
fore clinical relapse [7]. Early detection of relapse in pa-
tients with lower tumor burdens improves the chances 
of cure by salvage therapy [14]. Therefore, there may be a 
need to evaluate the role of FDG-PET/CT according to 
histologic subtypes. To date, few studies have assessed 
the role of surveillance FDG-PET/CT while considering 
different subtypes, especially T-cell lineage lymphoma. 
More detailed analyses that include lymphoma subtypes 
could help determine the usefulness of surveillance 
FDG-PET/CT in certain clinical situations.
Hence, the aim of this study was to evaluate the posi-
tive predictive value (PPV) of surveillance FDG-PET/CT 
according to histologic findings, and to analyze the rate 
of associated second malignancies or transformation to 
other subtypes. Moreover, we attempted to compare the 
benefits of surveillance FDG-PET/CT among patients 




Data from 157 patients who were newly diagnosed with 
NHL between January 2003 and December 2013 at Sev-
erance Hospital were retrospectively analyzed. Their di-
agnoses were pathologically confirmed by hematology 
pathologists according to 2008 World Health Organiza-
tion criteria [15]. During the study period, 1,700 patients 
were newly diagnosed with NHL, of whom 1,314 were 
treated at our institution; 971 patients achieved a com-
plete response (CR) after first-line treatment. During the 
follow-up period, 157 patients showed positive findings 
on surveillance FDG-PET/CT within 5 years after achiev-
ing a CR, and all results were confirmed with biopsy at 
the suspicious site. We excluded patients with positive 
FDG-PET/CT findings discovered during unscheduled 
FDG-PET/CT scans, as well as patients whose diseases 
were not histologically confirmed. Upon diagnosis, pa-
tients underwent physical examination, FDG-PET/CT, 
bone marrow examination, and laboratory tests that 
included lactic dehydrogenase (LDH) measurement. 
The stage was assessed in accordance with the Ann 
Arbor staging system; lymphoma subtypes that do not 
use this staging system (such as cutaneous T-cell lym-
phoma) were excluded [16]. Each patient was stratified 
into one of four risk groups according to IPI criteria [17]. 
Secondary IPI was defined as IPI at the time of positive 
FDG-PET/CT findings. We classified lymphomas into 
indolent B-cell, aggressive B-cell, and aggressive T-cell 
NHLs [18]. Patients with lymphoma included 89 with 
DLBCL, 18 with marginal zone B-cell lymphoma, 20 
with follicular lymphoma, eight with mantle cell lym-
phoma (MCL), five with Burkitt lymphoma, one with 
lymphoblastic lymphoma, two with extranodal natural 
killer/T (NK/T)-cell lymphoma-nasal type, and 14 with 
peripheral T-cell lymphoma. MCL was scored accord-
ing to MCL IPI [19]. Six low risk patients were classi-
fied as having indolent B-cell NHL, while one patient 
with intermediate risk and another with high risk were 
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deemed to have aggressive B-cell NHL. This study was 
approved by the Institutional Review Board of Severance 
Hospital. Written informed consent by the patients was 
waived due to a retrospective nature of our study (IRB 
no. 3-2014-0289).
Response assessment and 18F-FDG-PET/CT
Responses were assessed after treatment completion 
according to International Working Group criteria us-
ing FDG-PET/CT [2]. Surveillance FDG-PET/CT was 
performed at 6-month intervals in the first 2 years and 
every other year for up to 5 years. Patients with positive 
FDG-PET/CT findings underwent biopsies at FDG up-
take sites. FDG-PET/CT results were reviewed visually 
by experienced nuclear medicine physicians. Positive 
scans were defined as the appearance of newly devel-
oped uptake relative to that in the mediastinal blood 
pool; negative scans were considered a lack of evidence 
of disease [20,21]. Patients with FDG uptake owing to 
suspected physiologic responses were not included in 
this study. The five-point visual assessment method was 
used to score FDG uptake [22]. Patients with Deauville 
scores of 1 or 2 were not included in this study, as these 
scores were interpreted as negative findings.
Statistical methods
We categorized patients according to true or false posi-
tive findings; PPV was defined as the proportion of true 
positive patients among those with positive surveillance 
FDG-PET/CT findings. “True positive” was defined as 
FDG uptake on FDG-PET/CT that was histologically 
confirmed as relapsed lymphoma, while “false positive” 
was defined as no evidence of recurred lymphoma on 
biopsy. The statistical significance of categorical vari-
ables was calculated using chi-squared tests. p values < 
0.05 were considered statistically significant in all tests. 
All statistical analyses were performed using SPSS for 
Windows version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics
During a median follow-up period of 47.0 months 
(range, 7 to 133), 1,186 FDG-PET/CT images were ac-
quired, with 157 patients showing positive findings. Pa-
tient characteristics are summarized in Table 1. Among 
the 157 patients with positive FDG-PET/CT findings, 78 
(49.7%) were confirmed to have relapsed on biopsy, while 
79 (50.3%) had no evidence of relapse. PPVs of FDG-PT/
CT according to lymphoma aggressiveness are shown 
in Table 2. Among 971 patients, 90 patients diagnosed 
with relapse by symptoms and 69 patients underwent 
repeated biopsy. Relapse patients diagnosed by symp-
toms showed a higher PPV than those diagnosed by sur-
veillance PET/CT in all subtypes (indolent B-cell NHL: 
p = 0.013, aggressive B-cell NHL: p < 0.001, and T-cell 
NHL: p = 0.048).
Histological findings in the 79 false positive patients 
revealed eight secondary cancers (Table 3). FDG uptake 
in these patients was observed at extranodal sites that 
were distinct from the primary sites at diagnosis. The 
Table 1. Patient characteristics
Variable             Value
Age, yr (median) 55.5 (18–82)
Male sex 91 (58.0)
ECOG 0–1 146 (93)
Stage III/IV 89 (56.7)
Extranodal involvement > 1 48 (30.6)
Elevated LDH level 69 (43.9)
IPI
Low/low-intermediate 74 (47.1)/33 (21.0)
High-intermediate/high 36 (22.9)/14 (8.9)
Values are presented as median (range) or number (%).
ECOG, Eastern Cooperative Oncology Group; LDH, lactic dehydrogenase; IPI, international prognostic index.
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median age of these patients was 73 years (range, 57 to 79).
PPVs according to lymphoma subtype
Patient classification based on the subtype of lympho-
ma revealed that 44 patients had indolent B-cell NHL, 
96 had aggressive B-cell NHL, and 17 had aggressive 
T-cell NHL. PPV of aggressive B-cell NHL (38.5%) was 
significantly lower than those of indolent B-cell NHL 
(65.9%) and aggressive T-cell NHL (70.6%) (p = 0.003 and 
p = 0.018, respectively) (Table 2). There was no difference 
in PPV according to rituximab treatment in patients 
with aggressive B-cell NHL (p = 0.999) or those with in-
dolent B-cell NHL (p = 0.342). Analysis of durations since 
achieving CR showed that PPV of patients with aggres-
sive B-cell NHL (34.6%) was lower than that of patients 
with indolent B-cell NHL (62.1%) or aggressive T-cell 
NHL (64.1%) within 24 months (p = 0.015, p = 0.013, re-
spectively), although the difference was not significant 
after 24 months (p = 0.469) (Table 2).
Among 78 patients with true positive results, lym-
phoma transformed into a different subtype in seven 
(8.9%); four of these patients showed FDG uptake at 
sites other than the locations of their initial lesions, and 
five relapsed after 12 months of follow-up. These seven 
patients included four of 37 with aggressive B-cell NHL 
(10.8%) and three of 29 with indolent B-cell NHL (10.3%) 
with positive PPVs. None of the patients with aggressive 
T-cell NHL experienced subtype change (Table 4). High 
Deauville score was associated with high PPV. True pos-
itive and false positive rates were 26.1% and 73.9% in 
Deauville 3 group, 43.8% and 56.3% in Deauville 4, and 
59.3% and 40.7% in Deauville 5 group, respectively (p = 
0.011).
PPV according to IPI at diagnosis or relapse
There was no significant difference in PPVs between 
patients with low/low-intermediate risk and high-in-
termediate/high risk, as assessed by IPI at diagnoses (p 
= 0.734). Moreover, PPVs did not differ when analyzed 
according to individual IPI components, such as age > 
60 years (p = 0.327), Eastern Cooperative oncology Group 
(ECOG) performance status ≥ 2 (p = 0.765), stage ≥ III (p 
= 0.077), extranodal involvement at more than one site 
(p = 0.169), and elevated LDH levels (p = 0.631) at diagno-
sis. Among patients with low/low-intermediate risk IPIs 
at baseline, PPV of those with aggressive B-cell NHL 
(32.1%) was lower than those with indolent B-cell NHL 
(62.2%) and aggressive T-cell NHL (78.6%) (p = 0.006 
and p = 0.002, respectively). However, there was no PPV 
difference according to subtype among patients with 
high-intermediate/high risk baseline IPI (Table 5).
At the time of performing FDG-PET/CT, 119 patients 
(75.8%) were low risk, 25 (15.9%) were low-intermediate 
risk, 11 (7.0%) were high-intermediate risk, and two (1.3%) 
were high risk according to secondary IPIs. Patients 
with low/low-intermediate risk secondary IPIs had low-
er PPVs than patients with high-intermediate/high risk 
secondary IPIs (45.8% vs. 92.3%, p = 0.001); this finding 
was clinically significant only in patients with aggressive 
B-cell NHL (34.1% vs. 87.5%, p = 0.005). Among patients 
with low/low-intermediate risk secondary IPI, PPV of 
aggressive B-cell NHL was lower than those of indolent 
and aggressive T-cell NHLs (p = 0.001 and p = 0.040, re-
spectively). PPVs of aggressive T-cell and indolent B-cell 
NHL patients were 64.3% each in those with low/low-in-
termediate risk IPI. There was no difference in PPV 
according to lymphoma subtypes among patients with 
high-intermediate/high risk secondary IPI (Table 5).





PPV, % p value








PPV, % p value
Aggressive B-cell NHL 37/96 38.5 27/78 34.6 10/18 55.6
vs. Indolent B-cell NHL 29/44 65.9 0.003 18/29 62.1 0.015 11/15 73.3 0.469
vs. Aggressive T-cell NHL 12/17 70.6 0.018 12/17 70.6 0.013 0/0 0.0
Total 78/157 49.6
PPV, positive predictive value; NHL, non-Hodgkin’s lymphoma.
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DISCUSSION
We found that PPV of surveillance FDG-PET/CT is be-
low 50%, as more than half of the diagnoses turned out 
to be false positive when confirmed with biopsy. PPV 
of surveillance PET/CT was significantly lower than that 
of symptomatic relapse. This indicated that repeat bi-
opsies should be considered for asymptomatic patients 
with FDG uptake on surveillance FDG-PET/CT to iden-
tify false positive results. Our false positive rate was rel-
atively higher than in previous studies, as we included 
only results from asymptomatic patients with positive 
FDG-PET/CT results, and excluded data from patients 
with suspected clinical relapse. The most common his-
tologic finding among the 79 patients with false positive 
results was inflammation or reactive hyperplasia; more-
Table 3. Histologic findings in false positive patients
Variable Indolent B-cell NHL Aggressive B-cell NHL Aggressive T-cell NHL Total, no. (%)
Second cancer 1 7 0 8 (10.1)
Inflammation/reactive 13 43 3 59 (74.9)
Normal 1 9 2 12 (15.2)
Total 15 59 5 79
NHL, non-Hodgkin’s lymphoma.
Table 4. Patients with subtype changes
Lymphoma subtype







DLBCL LN LN FL
DLBCL LN LN FL
DLBCL Oropharynx Tonsil HL
DLBCL LN Lung MZBCL
FL Soft tissue LN DLBCL
FL LN LN DLBCL
MZBCL Lung Soft tissue DLBCL
DLBCL, diffuse large B-cell lymphoma; LN, lymph node; FL, follicular lymphoma; HL, Hodgkin lymphoma; MZBCL, mar-
ginal zone B-cell lymphoma. 
Table 5. Positive predictive values according to lymphoma subtypes and international prognostic index
Variable
Low/Low-intermediate High-intermediate/High
No. (positive/total) PPV p value No. (positive/total) PPV p value
IPI at baseline
Aggressive B-cell NHL 18/56 32.1 - 19/40 47.5 -
vs. Indolent NHL 23/37 62.2 0.006 6/7 85.7 0.102
vs. Aggressive T-cell NHL 11/14 78.6 0.002 1/3 33.3 0.999
IPI at relapse (secondary IPI)
Aggressive B-cell NHL 30/88 34.1 - 7/8 87.5 -
vs. Indolent NHL 27/42 64.3 0.001 2/2 100.0 0.999
vs. Aggressive T-cell NHL 9/14 64.3 0.040 3/3 100.0 0.999
PPV, positive predictive value; IPI, international prognostic index; NHL, non-Hodgkin’s lymphoma.
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over, eight were diagnosed with secondary malignan-
cies. High FDG uptake could help discriminate relapse 
from false positive results. Therefore, repeated biopsies 
would also serve to differentiate secondary malignancies 
from relapsed lymphoma or inflammation.
Notably, surveillance FDG-PET/CT had differing de-
grees of usefulness depending on the subtype of lym-
phoma. Although FDG-PET/CT for staging and re-
sponse evaluation can provide confirmative evidence of 
DLBCL, it is not as useful for its surveillance. There are 
some reports about the usefulness of surveillance PET/
CT for highly selective patients. We hypothesized that 
the role of surveillance PET/CT would differ according 
to the subtype of lymphoma. In patients with aggressive 
B-cell NHL, surveillance FDG-PET/CT imaging was 
shown to have a limited role in predicting relapse, es-
pecially in patients with low/low-intermediate risk IPIs 
at diagnosis and at the time of relapse. Aggressive B-cell 
NHL showed statistically low PPV of surveillance FDG-
PET/CT within the first 24 months. After 24 months, 
PPV of surveillance FDG-PET/CT in patients with ag-
gressive B-cell NHL was not different compared that of 
indolent lymphoma; this suggested that positive PET 
results should be interpreted carefully to discriminate 
the relapse.
One of the possible causes of the high false positive 
rate in aggressive B-cell NHL is suggested to be ritux-
imab, which is known to have relatively long-lasting 
inflammatory changes associated with the recruitment 
of immune cells to the tumor [23,24]. However, only a 
proportion of patients with aggressive or indolent B-cell 
NHL were treated with a rituximab-containing regimen 
in our study, and there was no significant difference in 
the false positive rate between such patients and those 
who did not receive the drug. Therefore, false positivity 
in patients with aggressive B-cell NHL may be partially 
attributed to the nature of lymphoma itself, in addition 
to any effect of rituximab. Based on the current guide-
lines, evaluation of complete blood count, metabolic 
panels, and serum LDH every 3 months could be suffi-
cient for patients with aggressive B-cell NHL.
PPV of surveillance FDG-PET/CT was relatively 
higher in patients with aggressive T-cell NHL than in 
those with aggressive B-cell NHL. In contrast to B-cell 
NHL, there are only a few existing studies of the role 
of FDG-PET/CT in T-cell NHL. Among patients with 
aggressive T-cell NHL in our study, 70% showed true 
relapse based on FDG-PET/CT results. The benefit of 
surveillance FDG-PET/CT was similarly evident even in 
patients with secondary low/low-intermediate IPI. This 
finding suggested that surveillance FDG-PET/CT could 
be useful for detecting relapse before symptoms occur 
in patients with aggressive T-cell NHL. Most aggressive 
T-cell NHLs are considered FDG-avid; they have short 
progression-free survival rates and frequently relapse. 
Hence, early detection of relapse could provide the op-
portunity for timely salvage treatment.
Indolent lymphoma progresses slowly; most patients 
were diagnosed with relapse through follow-up imag-
ing, rather than clinical signs or physical examination. 
In contrast, relapse of aggressive NHL was detected via 
clinical symptoms. PPV of FDG-PET/CT in patients 
with indolent NHL was relatively high, even in those 
with low/low-intermediate risk IPIs; although the de-
tection of relapse in these patients does not necessar-
ily require immediate treatment, transformation from 
indolent to aggressive NHL does require rapid detec-
tion and prompt intervention. Approximately 10% of 
patients with true positive results exhibited histologic 
subtype changes. In patients with indolent B-cell NHL, 
detecting any transformation to aggressive lymphoma 
is much more important than discovering a relapse of 
indolent lymphoma. Currently, there is no evidence to 
prove that early treatment of indolent lymphoma pro-
longs survival, and routine FDG-PET/CT is not rec-
ommended for such patients. However, there remains 
a need to identify the most accurate lesion with which 
to detect any transformation using FDG-PET/CT; of 
course, repeat biopsies play an invaluable role as well. 
Our study had some limitations. Given its retrospec-
tive, single-center nature, the enrollment of patients 
who received biopsies may have led to selection bias. 
There are many subtypes of lymphoma, and this study 
did not include enough patients to show a significance 
of difference subtypes. Still, all of the included patients 
underwent planned routine surveillance FDG-PET/CT 
at regular intervals. To specifically evaluate the role of 
routine surveillance FDG-PET/CT, patients with symp-
toms and signs of relapse were not included in this 
study. Moreover, we performed histologic confirmation 
of relapse via biopsy in all asymptomatic patients, and 
investigated the benefits of routine surveillance FDG-
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PET/CT in different lymphoma subtypes, as well as 
baseline or secondary IPI. Therefore, our findings will 
be useful for interpreting positive findings on routine 
surveillance FDG-PET/CT.
In conclusion, surveillance FDG-PET/CT produces 
varying PPVs according to the aggressiveness of lym-
phoma. While we confirmed that surveillance FDG-
PET/CT is of little use for patients with aggressive B-cell 
NHL, there remains a need to investigate any benefit for 
FDG-PET/CT in patients with aggressive T-cell NHL. 
Importantly, histologic confirmation by repeat biopsies 
should be required to rule out false positive findings 
and distinguish true relapse from subtype transforma-
tion or secondary malignancies.
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